Authors' Response to Letter to the Editor Regarding Comparative Efficacy of JAK Inhibitors for Moderate-to-Severe Rheumatoid Arthritis: A Network Meta-Analysis

Adv Ther. 2021 May;38(5):2750-2756. doi: 10.1007/s12325-021-01642-9. Epub 2021 Mar 20.

Authors

Janet Pope¹, Ruta Sawant², Namita Tundia², Ella X Du³, Cynthia Z Qi⁴, Yan Song⁴, Patrick Tang⁴, Keith A Betts³

Affiliations

¹ University of Western Ontario, London, ON, Canada. [email protected].
² AbbVie, Inc., North Chicago, IL, USA.
³ Analysis Group, Inc., Los Angeles, CA, USA.
⁴ Analysis Group, Inc., Boston, MA, USA.

No abstract available

Keywords: Clinical remission; Disease-modifying antirheumatic drugs; Janus kinase inhibitors; Network meta-analysis; Rheumatoid arthritis.

Publication types

Letter
Kommentar

MeSH terms

Antirheumatic Agents* / therapeutic use
Arthritis, Rheumatoid* / drug therapy
Humans
Janus Kinase Inhibitors* / therapeutic use
Network Meta-Analysis

Substances

Antirheumatic Agents
Janus Kinase Inhibitors